erc1671
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT01903330)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- erc1671
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05366062 | Phase 2 | Jul 1, 2022 | Epitopoietic Research Corporation |
| NCT01903330 | Phase 2 | Mar 1, 2014 | Epitopoietic Research Corporation, University of California, Irvine |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Epitopoietic Research Corporation | For profit | 2 | 1 | 1 | 2014 |
| University of California, Irvine | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1